Beta Bionics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $100.3M | $65.1M | $12.0M | — |
| Cost of revenue | $44.7M | $29.2M | $5.7M | — |
| Gross profit | $55.5M | $35.9M | $6.3M | — |
| Research and development | $34.8M | $26.2M | $17.9M | — |
| Operating expenses | $127.2M | $81.1M | $42.2M | — |
| Operating income | -$71.7M | -$45.3M | -$35.9M | — |
| Income tax expense | $0 | $0 | — | — |
| Net income | -$73.2M | -$54.8M | -$44.1M | — |
| Balance Sheet | ||||
| Cash and equivalents | $31.6M | $30.4M | $26.6M | — |
| Current assets | $267.9M | $132.9M | $103.6M | — |
| Total assets | $328.7M | $149.6M | $110.0M | — |
| Current liabilities | $30.9M | $21.1M | $10.6M | — |
| Total liabilities | $41.1M | $73.6M | $51.4M | — |
| Stockholders' equity | $287.6M | -$245.4M | -$203.1M | -$170.0M |
| Cash Flow Statement | ||||
| Cash from operations | -$50.9M | -$48.3M | -$32.4M | — |
| Depreciation and amortization | $1.6M | $1.2M | $1.2M | — |
| Stock-based compensation | $16.4M | $6.4M | $5.7M | — |
| Capital expenditure | $5.3M | $3.4M | $402,000 | — |
| Free cash flow | -$56.2M | -$51.7M | -$32.8M | — |
| Impairments | $0 | $0 | $0 | — |
Shares outstanding 44.6M · Free float 74.5%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.